@article{8a2a0340fe984bb2a5529b66278821c7,
title = "Control of fear by discrete prefrontal GABAergic populations encoding valence-specific information",
abstract = "Neurons activated by learning have been ascribed the unique potential to encode memory, but the functional contribution of discrete cell types remains poorly understood. In particular, it is unclear whether learning engages specific GABAergic interneurons and, if so, whether they differ functionally from interneurons recruited by other experiences. Here, we show that fear conditioning activates a heterogeneous neuronal population in the medial prefrontal cortex (mPFC) that is largely comprised of somatostatin-expressing interneurons (SST-INs). Using intersectional genetic approaches, we demonstrate that fear-learning-activated SST-INs exhibit distinct circuit properties and are selectively reactivated to mediate cue-evoked memory expression. In contrast, an orthogonal population of SST-INs activated by morphine experience exerts opposing control over fear and supports reward-like motivational effects. These results outline an important role for discrete subsets of GABAergic cells in emotional learning and point to an unappreciated capacity for functional specialization among SST-INs.",
keywords = "Pavlovian, engram, interneurons, medial prefrontal cortex, memory, morphine, somatostatin",
author = "Cummings, {Kirstie A.} and Sabina Bayshtok and Dong, {Tri N.} and Kenny, {Paul J.} and Clem, {Roger L.}",
note = "Funding Information: We thank Anosha Khawaja for animal care, Dr. Haruhiko Bito for sharing the E-SARE-ERCreER plasmid, and members of the Clem laboratory for helpful discussions. We also thank Dr. Marine Salery for advice regarding CPP experiments, and Dr. Abigale Lade for her immeasurable support. These experiments were supported by funds from the National Institute of Mental Health (NIMH) grants R01 MH116145 and R01 MH124880 to R.L.C. in addition to F32 MH115688 and K99 MH122228 to K.A.C. K.A.C. and R.L.C. initiated the project. R.L.C. P.J.K. and K.A.C. supervised research. K.A.C. and R.L.C. designed experiments. K.A.C. S.B. and T.N.D. performed the research and data analysis. R.L.C. and K.A.C. wrote the manuscript. P.J.K. is co-founder and shareholder in Eolas Therapeutics Inc. which has a licensing agreement with AstraZeneca to develop a novel therapeutic for the treatment of substance use disorders. Funding Information: We thank Anosha Khawaja for animal care, Dr. Haruhiko Bito for sharing the E-SARE-ERCreER plasmid, and members of the Clem laboratory for helpful discussions. We also thank Dr. Marine Salery for advice regarding CPP experiments, and Dr. Abigale Lade for her immeasurable support. These experiments were supported by funds from the National Institute of Mental Health (NIMH) grants R01 MH116145 and R01 MH124880 to R.L.C., in addition to F32 MH115688 and K99 MH122228 to K.A.C. Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",
year = "2022",
month = sep,
day = "21",
doi = "10.1016/j.neuron.2022.07.004",
language = "English",
volume = "110",
pages = "3036--3052.e5",
journal = "Neuron",
issn = "0896-6273",
publisher = "Cell Press",
number = "18",
}